TSHA Insider Trading Activity and SEC Form 4 Filings
TSHA insider trading summary
Over the past 12 months, insiders at Taysha Gene Therapies, Inc. (TSHA) reported 12 sales worth $6.7M by 3 insiders and no open-market purchases on SEC Form 4. Net insider selling was $6.7M.
Latest TSHA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 10, 2026 | Sukumar Nagendran | President and Head of R&D | Sell | $1.2M (200,000 @ $6.24) |
| Apr 10, 2026 | Sukumar Nagendran | President and Head of R&D | Sell | $892K (200,000 @ $4.46) |
| Feb 4, 2026 | Kamran Alam | Chief Financial Officer | Sell | $7K (1,655 @ $4.52) |
| Jan 26, 2026 | Kamran Alam | Chief Financial Officer | Sell | $110K (23,849 @ $4.61) |
| Jan 26, 2026 | Sean P. Nolan | Chief Executive Officer | Sell | $190K (41,312 @ $4.61) |
| Jan 26, 2026 | Sukumar Nagendran | President and Head of R&D | Sell | $124K (26,918 @ $4.61) |
| Jan 23, 2026 | Kamran Alam | Chief Financial Officer | Sell | $375K (78,968 @ $4.75) |
| Jan 23, 2026 | Sukumar Nagendran | President and Head of R&D | Sell | $423K (89,132 @ $4.75) |
| Jan 23, 2026 | Sean P. Nolan | Chief Executive Officer | Sell | $650K (136,789 @ $4.75) |
| Jan 12, 2026 | Sukumar Nagendran | President and Head of R&D | Sell | $942K (200,000 @ $4.71) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.